Clinical data generated with the anti-EGFR antibody nimotuzumab (2.1×10−8 M monovalent affinity [41]) suggests that moderate affinity can be sufficient for efficacy and may promote more selective tumor targeting and decreased systemic toxicities by requiring divalent binding of two EGFR molecules as part of its mechanism of action (reviewed in [42]). This evidence concerns the gene EGFR and neoplasm.